Top Markets
#1 Cortex Cortex +173.72%
#2 Helium Helium +60.27%
#3 GEKKO GEKKO +50.71%
#4 Pons Pons +20.78%
#5 ADO Protocol ADO Protocol +17.96%
#6 o1.exchange o1.exchange +13.64%
#7 Collect on Fanable Collect on Fanable +12.30%
#8 Status Status +11.10%
#9 龙虾 (Lobster) 龙虾 (Lobster) +10.81%
#10 Siren Siren +10.57%
Coin of the day
Cortex Cortex
Settings
Language
ENGLISH
Currency
USD
Theme
Chengdu Easton Biopharmaceuticals Co., Ltd. Chengdu Easton Biopharmaceuticals Co., Ltd.

Chengdu Easton Biopharmaceuticals Co., Ltd.

688513
Rank in Stocks #9010
Chengdu Easton Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise... Chengdu Easton Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the full spectrum of drug development, encompassing research, development, production, and market distribution of medicinal products. The company offers finished medications tailored for various medical disciplines, including pain management (anesthetics/analgesics), cardiovascular health, oncology, and pediatrics. Beyond ready-to-use drugs, it also manufactures active pharmaceutical ingredients (APIs) for a broader range of therapeutic areas, such as cancer treatment, heart conditions, pain relief, anti-inflammatory uses, gastrointestinal issues, antiemetics, neurological and psychiatric disorders, and urinary system ailments. Established in 2009, the firm is headquartered in Chengdu, China.
Share Price
$6.32
Last synced: 2026-08-28
Market Cap
$1.11B
Change (1 day)
-1.63%
Change (1 year)
-31.28%
Country
CN
Trade Chengdu Easton Biopharmaceuticals Co., Ltd. (688513)

Category

Healthcare
Revenue for Chengdu Easton Biopharmaceuticals Co., Ltd. (688513)
Revenue in Aug 2026 TTM: 0
According to Chengdu Easton Biopharmaceuticals Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Chengdu Easton Biopharmaceuticals Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH